MSA Safety Incorporated (MSA)
$
164.21
+1.88 (1.14%)
Key metrics
Financial statements
Free cash flow per share
6.4470
Market cap
6.4 Billion
Price to sales ratio
3.5147
Debt to equity
0.4602
Current ratio
2.9353
Income quality
1.0731
Average inventory
301.7 Million
ROE
0.2567
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
MSA Safety Incorporated develops, manufactures, and supplies a wide range of safety products aimed at protecting individuals and facilities in various industries, including oil, gas, petrochemical, fire service, construction, industrial manufacturing, utilities, military, and mining across North America, Latin America, and internationally. The company recorded an operating income of $389,177,000.00 reflecting its earnings from core operations. Its gross profit stands at $860,445,000.00 highlighting the company's profitability from core operations. The cost of revenue for the company is $947,695,000.00 showcasing its production and operational expenses, while the company incurred an income tax expense of $90,039,000.00 indicating its tax obligations. The weighted average number of shares outstanding is 39,362,000.00 emphasizing the company's shareholder base. MSA's core product offerings include permanently installed fixed gas and flame detection instruments, breathing apparatus products such as self-contained breathing apparatuses, hand-held portable gas detection instruments, industrial head protection products, firefighter helmets and protective apparel, and fall protection gear including confined space equipment, harnesses, lanyards, and self-retracting lifelines. The company also provides air-purifying respirators, eye and face protection products, ballistic helmets, and gas masks, serving distributors and end-users through both direct and indirect sales channels, under brands like V-Gard, Cairns, and Gallet. The stock is reasonably priced at $162.33 appealing to a broad range of investors, although it has a low average trading volume of 234,733.00 indicating lower market activity. With a mid-range market capitalization of $6,454,421,839.00 the company is a steady performer and a key player in the Security & Protection Services industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Industrials sector, driving innovation and growth while ensuring the safety and security of personnel and infrastructure in critical environments.
Investing in MSA Safety Incorporated (MSA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict MSA Safety Incorporated stock to fluctuate between $127.86 (low) and $200.61 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-05-29, MSA Safety Incorporated's market cap is $6,454,421,839, based on 39,305,900 outstanding shares.
Compared to GE Aerospace, MSA Safety Incorporated has a Lower Market-Cap, indicating a difference in performance.
MSA Safety Incorporated pays dividends. The current dividend yield is 1.30%, with a payout of $0.53 per share.
To buy MSA Safety Incorporated (MSA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for MSA. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
MSA Safety Incorporated's last stock split was 3:1 on 2004-01-29.
Revenue: $1,808,140,000 | EPS: $7.24 | Growth: 385.91%.
Visit https://www.msasafety.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $200.61 (2024-07-16) | All-time low: $108.75 (2022-09-27).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
PITTSBURGH , May 15, 2025 /PRNewswire/ -- MSA Safety Incorporated (NYSE: MSA), a global leader in the development of advanced safety products and solutions that protect people and facility infrastructures, announced its participation in the following upcoming investor conferences. Conference 25 th Annual B.
globenewswire.com
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- LEEF Brands Inc. (CSE: LEEF) (OTCQB: LEEEF) (“LEEF” or the “Company”), one of California's premier vertical extraction companies, today announced a Management Services Agreement (“MSA”) with Glass House Brands, Inc. (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), a leading vertically integrated cannabis operator in the United States. Under the MSA, Glass House will manage operations of LEEF's Palm Desert, California, dispensary, “The Leaf El Paseo,” on behalf of LEEF.
globenewswire.com
LONG BEACH, Calif. and TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF) – one of the fastest-growing, vertically integrated cannabis companies in the United States, and LEEF Brands, Inc. (CSE: LEEF) (OTCQB: LEEEF), one of California's premier vertical extraction companies, today announced a Management Services Agreement (“MSA”). Under the MSA, Glass House will manage operation of LEEF's Palm Desert, CA dispensary “The LEAF El Paseo” on behalf of LEEF.
globenewswire.com
– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows higher α- synuclein concentration is associated with greater burden of orthostatic symptoms – MELBOURNE, Australia and SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that several oral and poster presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) were featured at the 2025 International MSA Congress. The Congress was presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support services, educational resources, research funding, and community engagement.
prnewswire.com
Acquisition expands MSA's Detection solutions and adds new capabilities in the gas analysis and process safety markets With annual revenue of approximately $55 million, M&C TechGroup is highly complementary to MSA's technology, customer base and distribution network Transaction expected to be accretive to MSA's adjusted earnings in 2025 PITTSBURGH , May 7, 2025 /PRNewswire/ --Global safety equipment and solutions provider MSA Safety Incorporated (NYSE: MSA) today announced it has acquired M&C TechGroup in a transaction valued at approximately $200 million. Based in Ratingen, Germany, M&C TechGroup provides a comprehensive range of gas analysis systems that detect, measure and monitor gases in critical environments.
prnewswire.com
PITTSBURGH , May 2, 2025 /PRNewswire/ -- The Board of Directors of MSA Safety Incorporated (NYSE: MSA) today approved the company's 55th consecutive annual dividend increase, raising the quarterly dividend from $0.51 per common share to $0.53 per common share. The change reflects a 4% increase in the quarterly dividend and a 5% increase in 2025 dividends per common share compared to 2024.
seekingalpha.com
MSA Safety Incorporated (NYSE:MSA ) Q1 2025 Earnings Conference Call April 30, 2025 10:00 AM ET Company Participants Larry De Maria - Executive Director of IR Steven Blanco - President and CEO Elyse Brody - Interim CFO Conference Call Participants Rob Mason - Baird Ross Sparenblek - William Blair Jeff Van Sinderen - B. Riley FBR Mike Shlisky - D.A.
globenewswire.com
Highlights Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust clinical efficacy Phase 2 data featured in an oral presentation at the American Academy of Neurology Annual Meeting ATH434-202 open-label trial in advanced MSA completed in March 2025 Cash balance on 31 March 2025 of A$17.96M with an additional A$27.1M raised subsequent to the end of the quarter MELBOURNE, Australia and SAN FRANCISCO, April 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2025 (Q3 FY25). David Stamler, M.D.
prnewswire.com
First Quarter 2025 Highlights Achieved quarterly net sales of $421 million, a 2% GAAP increase and 4% organic(a) increase year-over-year Generated GAAP operating income of $78 million, or 18.5% of sales, and adjusted operating income of $88 million, or 20.8% of sales Recorded GAAP net income of $60 million, or $1.51 per diluted share, and adjusted earnings of $66 million, or $1.68 per diluted share Returned capital to shareholders through $20 million of dividends and $10 million of share repurchases, invested $11 million for capital expenditures, and repaid $7 million of debt; closed an extended, upsized Revolving Credit Facility in April, which provides capacity of $1.3 billion PITTSBURGH , April 29, 2025 /PRNewswire/ -- Global safety equipment and solutions provider MSA Safety Incorporated (NYSE: MSA) today reported financial results for the first quarter of 2025. "Our solid first quarter results demonstrate the team's continued dedication to executing our Accelerate strategy.
globenewswire.com
MELBOURNE, Australia and SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer presented the ATH434-201 Phase 2 clinical trial results at the annual MSA Research Symposium hosted by University College London, Institute of Neurology in partnership with the MSA Trust of the U.K.
See all news